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who	 died	within	 6	months	 of	 drug	 induced	 liver	 injury.	 If	 confirmed	 prospectively,	
miRNA-	122	and	albumin	may	be	useful	in	identifying	patients	at	high	risk	for	mortality	
or	liver	transplantation.











tients	with	 DILI.	 Diagnosing	 DILI	 can	 be	 difficult,	 and	 except	 for	 a	
positive	 rechallenge,	 there	 is	no	clear	gold	 standard	 for	establishing	
the	diagnosis.	Common	ways	to	make	a	diagnosis	DILI	are	by	expert	
Abbreviations:	DILI,	 drug	 induced	 liver	 injury;	DILIN,	Drug	 Induced	 Liver	 Injury	Network;	
miRNA,	micro	RNA;	RFU,	relative	fluorescent	unit;	RMA,	robust	multichip	averaging.
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opinion	or	RUCAM,	both	of	which	have	their	limitations.4,5	After	the	






















The	 study	 population	 has	 been	 previously	 described.10,16	 Subjects	
were	 enrolled	 in	 the	 prospective	 study	 of	 the	 Drug	 Induced	 Liver	
Injury	Network	(DILIN)	and	followed	up	for	a	minimum	of	6	months	
after	the	event.	Briefly,	serum	samples	and	detailed	clinical	data	were	





trols	 were	 recruited	 from	 the	 Indiana	 University-	Purdue	 University	
site.	Clinical	data	were	 reviewed	by	 the	DILIN	causality	 committee,	
which	adjudicated	cases	as	unlikely,	possible,	probable,	very	likely	or	
definite	and,	 in	cases	 involving	multiple	drugs,	assigned	each	drug	a	
score.	Types	of	 liver	 injury	 (hepatocellular,	mixed,	 cholestatic)	were	
classified	by	R	values.10
We	 studied	 78	 subjects	 with	 acute	 DILI	 enrolled	 between	
December	 2004	 and	 July	 2010	 who	 had	 serum	 samples	 obtained	
within	 2	weeks	 of	 clinical	 onset.	Whenever	 possible	 subjects	 were	







miRNAs	 were	 isolated	 from	 200	μL	 of	 serum	 using	 miRNeasy	
Mini	 Kit	 (Qiagen,	 Valencia,	 CA,	 USA).	 The	 samples	 were	 ligated	 to	
biotinylated	signal	molecules	using	FlastTag™	Biotin	HSR	RNA	labelling	
Kit	 (Genisphere	 LLC,	Hatfield,	 PA,	USA).	An	 enzyme	 linked	oligoab-
sorbant	 assay	 (ELOSA)	 QC	 assay	was	 performed	 to	 verify	 labelling	
prior	 to	array	hybridization.	Samples	were	hybridized	 to	GeneChip® 
3.0	miRNA	microarrays	(Affymetrix,	Santa	Clara,	CA,	USA).	This	chip	
contains	 1733	probes	 for	 human	mature	miRNAs	 and	1658	probes	
for	 human	 pre-	miRNAs.	 Probe	 level	 signal	 intensities,	 expressed	 as	
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miRNA	with	the	best	predictive	results	(measured	by	overall	concor-












No	 subject	 underwent	 liver	 transplantation.	 The	 mean	 age	 of	 the	
DILI	cohort	was	48	years-	old	and	the	majority	were	female	(55%)	and	
Caucasian	(73%).	The	majority	of	subjects	(55%)	exhibited	hepatocel-






3.1 | Acute drug induced liver injury and miRNA 
levels results
Among	 1733	miRNAs	 and	 1658	 precursor	miRNAs	 analysed,	 eight	
were	 statistically	 higher	 in	 acute	 DILI	 cases	 compared	 to	 controls	
(miR-	122,	 -	1246,	 -	4270,	 -	4433,	 -	4463,	 -	4484,	 -	4532,	 and	 pre-	




3.2 | miRNA levels and death within 6 months of 
DILI onset
Three	 miRNAs	 were	 associated	 with	 death	 within	 6	months	 (miR-	
122,	 -	4463,	 pre-	miR-	4270,	P<.05)	 among	11	miRNAs	 analysed	 and	
five	were	associated	with	death	at	any	time	(miR-	122,	-	4463,	-	4270,	





78 subjects with acute DILI enrolled 2004-2012
11 subjects died within
6 months of DILI onset
32 subjects completed
6 months of follow-up
36 subjects did not complete 6
months of follow-up
Figure 1: Flow diagram of study populaon
Sera from 78 DILI subjects and 40 healthy controls were analyzed.










Age,	mean	(SD)	years 48±17.9 51±14.2 49.2±13.1
Female	(%) 55 55 28
Self	reported	race	(%)
White 73 73 95
Black 10 10 5








ALT	(U/L) 1065±1382 55±131 17.5±5
















P=.001.	 Similarly,	 pre-	miR-	4270	 levels	were	 higher	 in	DILI	 subjects	
who	survived	at	least	6	months	compared	to	controls,	3.80	and	2.14,	
RFU/200 μL,	respectively,	P=.007,	as	were	miR-	4463	levels,	5.20	and	
2.92,	 respectively,	 P=.003	 (Figure	3).	 Mean	 levels	 of	 miRNA	 levels	
were	not	significantly	different	between	serum	samples	collected	on	
days	1–7	vs	8–14	after	onset	of	acute	injury.





















The	major	 findings	 of	 this	 study	 are	 that,	 (i)	 Among	 3391	miRNAs	
and	pre-	miRNAs	tested,	only	11	were	significantly	different	between	














T A B L E  3  Characteristics	of	subjects	who	died
Subject Implicated drug(s)
Days to 
death Cause of death
1 Oxacillin 102 Drug	overdose













6 Nitrofurantoin 6 Liver	related
7 Ciprofloxacin,	niacin 6 Liver	related
8 Antithymocyte	globulin 6 Aplastic	anaemia
9 Carbamezepine 21 Thymoma
10 Amiodarone,	nafcillin 40 Liver	related
11 Phenytoin 315 Liver	related



























Fold change in miRNA in DILI cases compared to controls
122 4532 4463 1246 4270 4484 4433 4467 455-3p 1281 4274
     |  761RUSSO et al.
subjects	with	acute	DILI	and	normal	controls,	with	eight	significantly	
higher	and	 three	significantly	 lower;	and	 (ii)	A	model	 that	uses	only	
the	relative	levels	of	miR-	122,	the	miRNA	most	significantly	elevated	
in	 acute	DILI,	 and	 level	 of	 serum	albumin	proved	 to	have	excellent	
prognostic	value	regarding	which	subjects	with	acute	DILI	will	live	or	
die	within	6	months	of	the	acute	event.
Identifying	biomarkers	 that	can	predict	 serious	acute	 liver	 injury	
from	drugs	may	have	practical	implications	for	clinical	practice	as	well	





























































































































































































significantly	 different	 in	 patients	 compared	 to	 controls;	 expression	
of	 eight	miRNAS	were	 increased	 compared	 to	 controls	 and	 the	 ex-
pression	of	three	miRNAS	were	lower	compared	to	controls.	We	have	
previously	 shown	 that	 a	panel	 of	 four	 immune	analytes	 (IL-	9,	 IL-	17,	




Among	 the	 increased	 miRNAs,	 miR-	122	 has	 been	 the	 most	 ex-
tensively	studied	and	more	than	70%	of	miRNA	Is	from	the	liver.24	Its	
level	 in	 serum	 is	 increased	 in	 hepatitis	 B,	 hepatitis	 C,	 non-	alcoholic	
fatty	 liver	 disease	 and	 decreased	 in	 hepatocellular	 carcinoma,	 fibro-
sis,	cirrhosis	and	metabolic	disorders.24	miR-	122	has	previously	been	





miR-	122	 has	 been	 implicated	 in	 the	 regulation	 of	
7-	alpha-	hydroxlyase	 translation,	 an	 enzyme	 involved	 in	 cholesterol	
metabolism,	 the	 regulation	 of	 hepatocyte	 differentiation,	 and	 he-
patocyte	regeneration.15	It	has	also	been	shown	to	be	important	for	
replication	 of	 hepatitis	C	virus	 in	 hepatocytes,	 and	 the	 hepatitis	C	
virus	has	 recently	been	 identified	 to	be	 a	 “sponge”	 that	 “soaks	up”	
miR-	122	 in	 infected	 hepatocytes,	 preventing	 the	 action	 of	 Xrn2,	 a	





functions	 of	 the	 other	miRNAs	 associated	with	mortality	 from	DILI	
are	not	as	well	studied.	miR-	4270	has	been	associated	with	regulat-
ing	 early	 cellular	 differentiation	 and	 URG4/URGCP	 oncogene	 and	
renal cell carcinoma.30	miRNA-	4463	has	been	associated	with	insulin	
	resistance	and	polycystic	ovary	syndrome.31,32	A	study	of	miR-	1246	
demonstrated	 an	 association	 with	 increased	 hepatic	 differentiation	
in	mesenchymal	cells.33	Further	elucidation	of	 the	 function	of	 these	
miRNAs	is	needed	to	determine	if	there	is	biologic	plausibility	for	their	
association	with	mortality	from	DILI.










We	 demonstrated	 that	 subjects	 with	 serum	 albumin	 <2.8	g/dL,	
with	 miRNA-	122<7.89	 accurately	 identified	 those	 at	 highest	 risk	
for	 death.	 In	 fact,	 our	model	 performed	better	 than	MELD	 score	 in	
predicting	 outcomes.	 In	 general,	 tests	 that	 accurately	 predict	 death	
from	acute	 liver	failure	are	 lacking	and	there	are	no	biomarkers	that	
























* * * 












low	 albumin	was	 from	 hepatic	 synthetic	 dysfunction	 and	 not	 other	
causes	 of	 hypoalbuminaemia	 such	 as	 nephrotic	 syndrome.	 In	 other	
recent	work,	we	demonstrated	 that	 serum	albumin	 levels	 <2.8	g/dL	




including	 levels	 of	 cytokines	 and	miRNAs	 into	 a	model	 for	 predict-























group.	Such	 further	 studies	are	 in	progress	 in	DILIN.	miRNA-	122	 in	
combination	with	 albumin	appears	 to	be	 the	most	promising	model	
for	further	study.
In	 conclusion,	 the	 serum	 level	 of	 miRNA-	122,	 especially	 when	
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